Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
10x GenomicsTXG +1.46%60 Earnings per Share (Diluted) is $-0.59 as of Jun. 2026. GuruFocus rates TXG with a GF Score™ of 60/100 and a GF Value™ of $18.36 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 505 Healthcare Providers & Services companies, 10x Genomics ranks better than 63.37% on this metric.
10x Genomics's EPS (Basic) for the
three
months ended in Jun. 2026 was $-0.14.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Jun. 2026 was $-0.59.
10x Genomics's EPS without NRI for the
three
months ended in Jun. 2026 was $-0.17.
Its EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2026 was $-0.62.
During the past 3 years, the average EPS without NRIGrowth Rate was 23.00% per year.
During the past 5 years, the average EPS without NRIGrowth Rate was 6.80% per year.
During the past 9 years, 10x Genomics's highest 3-Year average EPS without NRI Growth Rate was 23.00% per year. The lowest was -110.90% per year. And the median was -11.75% per year.
10x Genomics (NAS:TXG) Earnings per Share (Diluted) Explanation
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
10x Genomics Earnings per Share (Diluted) Related Terms
10x Genomics Earnings per Share (Diluted) Historical Data
* Premium members only.
The historical data trend for 10x Genomics's Earnings per Share (Diluted) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TXG vs HQY, HNGE, WAY: Earnings per Share (Diluted) Comparison
For the Health Information Services subindustry, 10x Genomics's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
10x Genomics PE Ratio vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, 10x Genomics's PE Ratio distribution charts can be found below:
* The bar in red indicates where 10x Genomics's PE Ratio falls into.
10x Genomics Earnings per Share (Diluted) Calculation
Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.
10x Genomics's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2025 is calculated as
Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.59
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.
What does a Earnings per Share (Diluted) of $-0.59 mean?
10x Genomics (TXG) has a Earnings per Share (Diluted) of $-0.59 as of Jun. 2026. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on 10x Genomics and its competitors. According to the industry distribution chart, 10x Genomics ranks #185 out of 505 companies in the Healthcare Providers & Services industry, placing it in the top 36.6%.
Is 10x Genomics' Earnings per Share (Diluted) too high?
10x Genomics' current Earnings per Share (Diluted) is $-0.59. Based on the distribution chart, 10x Genomics ranks #185 out of 505 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, 10x Genomics has a GF Score™ of 60/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does 10x Genomics' Earnings per Share (Diluted) compare to HQY and HNGE?
According to the Healthcare Providers & Services industry distribution chart, 10x Genomics ranks #185 out of 505 companies for Earnings per Share (Diluted). This puts 10x Genomics in the upper half of its industry. The industry median Earnings per Share (Diluted) is 11.00. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings per Share (Diluted) for a Healthcare Providers & Services company?
The median Earnings per Share (Diluted) among Healthcare Providers & Services companies is 11.00, based on 505 companies in the industry. Companies in the top quartile (top 25%) have a Earnings per Share (Diluted) significantly above this median, while those in the bottom quartile fall well below. However, Earnings per Share (Diluted) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings per Share (Diluted) mean?
A high Earnings per Share (Diluted) can signal that a stock is expensive relative to its fundamentals. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on 10x Genomics and its competitors. For the Healthcare Providers & Services industry, the median Earnings per Share (Diluted) is 11.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. 10x Genomics's current Earnings per Share (Diluted) is $-0.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is 10x Genomics stock overvalued right now?
Based on GuruFocus' analysis, 10x Genomics (TXG) is currently considered Significantly Overvalued. The stock's GF Value™ is $18.36, compared to a current price of $62.45 — trading 240.1% above its estimated fair value. The current Earnings per Share (Diluted) is $-0.59. 10x Genomics' overall GF Score™ is 60/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings per Share (Diluted) calculated?
Earnings per Share (Diluted) is calculated from a company's financial statements. For 10x Genomics (TXG), the current Earnings per Share (Diluted) is $-0.59 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is 10x Genomics (TXG) Overvalued in 2026?
Based on GuruFocus' analysis, 10x Genomics stock appears to be overvalued.
The current stock price of $62.45 is trading 240.1% above its estimated GF Value™ of $18.36.
GuruFocus considers 10x Genomics to be Significantly Overvalued.
Key valuation signals for TXG:
Earnings per Share (Diluted): $-0.59
GF Value™: $18.36 vs. price of $62.45 (240.1% above fair value)
No single metric tells the full story. See the TXG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The company's integrated solutions include instruments, consumables, and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. Its product offerings include a Chromium platform comprising microfluidic chips and related consumables, Chromium X series, Visium and Xenium platforms, and others, which are predominantly used for the study of biological components. Geographically, the company derives operates from the United States and the rest from Americas (excluding the United States), Europe, Middle East and Africa, China, and Asia-Pacific (excluding China).
60GF Score
Get the complete analysis for TXG
Earnings per Share (Diluted) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TXG has been successfully added to your 
